{
  "trial_id": "NCT01709474",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Written informed consent signed by the subject or parent/guardian as appropriate",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "child assent as appropriate",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Before the age of 19, met at least 4 of the 11 modified American College of Rheumatology (ACR) 1982 Revised Criteria for the Classification of Systemic Lupus Erythematosus as updated in 1997",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "to randomization",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Serum 25-hydroxyvitamin D [25(OH)D] < 20 ng/mL at Screening",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "SELENA SLEDAI score > 0 and < 8 at Screening and at Baseline",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "If taking prednisone (or equivalent corticosteroid), the dose must be \u2264 15 mg/day or \u22640.5 mg/kg/day, whichever is lower, and stable for at least four weeks prior to randomization",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Stable immunosuppressive dose for at least 12 weeks prior to randomization",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Body weight > 25 kg",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Able to swallow pills",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Males and females with reproductive potential must agree to practice effective measures of birth control",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "exclusion": [
    {
      "criterion": "Any condition or treatment that, in the opinion of the investigator, places the subject at an unacceptable risk as a participant in the trial",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Current pharmacologic vitamin D2 or D3 intake > 800 IU daily or use of calcitriol at any dose over the past four weeks prior to randomization",
      "label": "not_met",
      "evidence": "quote"
    },
    {
      "criterion": "Cyclophosphamide or IV glucocorticoid exposure within 12 weeks prior to randomization",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Any BILAG A or B manifestation with the exception of a BILAG B mucocutaneous manifestation at screening, and excluding the renal BILAG criteria (see rituximab or belimumab criterion, below)",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Significant renal insufficiency defined as: Estimated GFR < 60 mL/min/1.73m^2 or estimated GFR < 90 mL/min/1.73m^2 with a reduction of the GFR by > 15% from the last measurement",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Rituximab or belimumab exposure use within 24 weeks prior to randomization",
      "label": "not_met",
      "evidence": "quote"
    }
  ],
  "notes": "The patient has Hashimoto disease, which may be relevant for the study. However, there is no clear indication that she would not meet the inclusion criteria or be excluded from the trial.",
  "_meta": {
    "topic_id": "66",
    "trial_id": "NCT01709474",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}